| [Fire Fighting] Wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Use agent most appropriate to extinguish fire. | |
| [Ingestion] Seek medical attention. If individual is drowsy or unconscious, do not give anything by mouth; place individual on the left side with the head down. Contact a physician, medical facility, or poison control center for advice about whether to induce vomiting. If possible, do not leave individual unattended. | |
| [Inhalation] If symptoms develop, move individual away from exposure and into fresh air. If symptoms persist, seek medical attention. If breathing is difficult, administer oxygen. Keep person warm and quiet; seek immediate medical attention. | |
| [Skin] Flush skin with plenty of soap and water for at least 15 minutes while removing contaminated clothing and shoes. | |
| [Eyes] Manufacturer recommendations include caution in handling ganciclovir formulations (intravenous {alkaline ph 11} or oral) and to avoid direct contact with skin or mucous membranes. | |
| [Storage] Keep in a cool, dry, dark location in a tightly sealed container or cylinder. Keep away from incompatible materials, ignition sources and untrained individuals. Secure and label area. Protect containers/cylinders from physical damage. | |
| [Handling] All chemicals should be considered hazardous. Avoid direct physical contact. Use appropriate, approved safety equipment. Untrained individuals should not handle this chemical or its container. Handling should occur in a chemical fume hood. | |
| [Inhalation] Pneumonia, dyspnea, and cough have been reported with ganciclovir. | |
| [Skin] Pruritus, rash, and sweating were the most frequent dermatologic complaints associated with intravenous or oral ganciclovir. | |
| [Ingestion] Vomiting, diarrhea, and anorexia have been reported in clinical trials. Upper gastrointestinal bleeding has occurred following ganciclovir therapy. | |
| [Personal Protection] Chemical splash goggles in compliance with OSHA regulations are advised; however, OSHA regulations also permit other type safety glasses. Whre chemical resistant gloves. To prevent repeated or prolonged skin contact, wear impervious clothing and boots. | |
| [Respirators] Use NIOSH/MSHA approved respirator appropriate for exposure of concern. | |
| [Exposure Effects] Fever has occurred with ganciclovir therapy. neuropathy and paresthesia have occurred during clinical trials with immunocompromised patients. Seizures associated with ganciclovir use have also occurred. Ganciclovir is classified by the manufacturer as US FDA pregnancy category C. | |
| [Appearance] Crystals from methanol. | |
| [Solubility in water] Very soluble | |
| [Melting Point] 250 | |
| [pKa/pKb] 9.15 (pKa) | |
| [Partition Coefficient] -2.07 | |
| [Heat Of Vaporization] | |
| [Usage] Medication. | |
| [Product Name] 9-(1,3-Dihydroxy-2-propoxymethyl)guanine | |
| [Synonyms] 2-Amino-1,9-((2-hydroxy-1-(hydroxymethyl)ethoxy)methyl)-6-h-purin-6-one 2-Amino-9-((1,4-dihydroxybutan-2-yloxy)methyl)-3H-purin-6(9H)-one 6H-Purin-6-one, 2-amino-1,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]- 9-(1,3-Dihydroxy-2-propoxymethyl)guanine Cymevan Hydroxyacyclovir | |
| [CAS] "CASEN_82410-32-0.htm">82410-32-0 | |
| [Formula] C9H13N5O4 | |
| [Molecular Weight] 255.23 | |
| [RTECS] MF8407000 | |
| [RTECS Class] Drug; Mutagen | |
| [Merck] 12,4374 | |
| [Beilstein/Gmelin] 3654487 | |
| [Small spills/leaks] Evacuate area and ventilate. Wear protective equipment. If required, use an inert absrobent. Sweep up and place in an appropriate container for disposal. Wash contaminated surfaces. | |
| [Stability] Exposure to temperatures exceeding 40 C should be avoided. When stored as directed, the sterile powder has an expiration date of 3 years following the date of manufacture. | |
| [Incompatibilities] Strong oxidizing agents. |
Print